T-cell receptor-engineered T cells for cancer treatment: current status and future directions

Yu Ping; Chaojun Liu; Yi Zhang

doi:10.1007/s13238-016-0367-1

Volume 9 Issue 3

Mar. 2018

Turn off MathJax

Article Contents

Article Navigation > Protein&Cell > 2018 > 9(3): 254-266

Yu Ping, Chaojun Liu, Yi Zhang. T-cell receptor-engineered T cells for cancer treatment: current status and future directions[J]. Protein&Cell, 2018, 9(3): 254-266. doi: 10.1007/s13238-016-0367-1

Citation:

Yu Ping, Chaojun Liu, Yi Zhang. T-cell receptor-engineered T cells for cancer treatment: current status and future directions[J]. Protein&Cell, 2018, 9(3): 254-266. doi: 10.1007/s13238-016-0367-1

Yu Ping, Chaojun Liu, Yi Zhang. T-cell receptor-engineered T cells for cancer treatment: current status and future directions[J]. Protein&Cell, 2018, 9(3): 254-266. doi: 10.1007/s13238-016-0367-1

Citation:

Yu Ping, Chaojun Liu, Yi Zhang. T-cell receptor-engineered T cells for cancer treatment: current status and future directions[J]. Protein&Cell, 2018, 9(3): 254-266. doi: 10.1007/s13238-016-0367-1

PDF( 1034 KB)

T-cell receptor-engineered T cells for cancer treatment: current status and future directions

doi: 10.1007/s13238-016-0367-1

Yu Ping¹,
Chaojun Liu¹,
Yi Zhang^{1,2,3
,}

1 Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China;
2 Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China;
3 Engineering Key Laboratory for Cell Therapy of Henan Province, Zhengzhou 450052, China

Funds:

This study was supported by grants from the National Natural Science Foundation of China (Grant Nos. 81171986, and 81271815), Research Grant from the Ministry of Public Health (No. 201501004), the National Key Research and Development Program of China (2016YFC1303501), Major Science and Technology Projects of Henan Province (1611003101000).

Received Date: 2016-10-31
Rev Recd Date: 2016-12-16

Abstract

Abstract

T-cell receptor (TCR)-engineered T cells are a novel option for adoptive cell therapy used for the treatment of several advanced forms of cancer. Work using TCRengineered T cells began more than two decades ago, with numerous preclinical studies showing that such cells could mediate tumor lysis and eradication. The success of these trials provided the foundation for clinical trials, including recent clinical successes using TCRengineered T cells to target New York esophageal squamous cell carcinoma (NY-ESO-1). These successes demonstrate the potential of this approach to treat cancer. In this review, we provide a perspective on the current and future applications of TCR-engineered T cells for the treatment of cancer. Our summary focuses on TCR activation and both pre-clinical and clinical applications of TCR-engineered T cells. We also discuss how to enhance the function of TCR-engineered T cells and prolong their longevity in the tumor microenvironment.
- T-cell receptor,
- tumor antigen,
- TCRengineered T cells,
- neoantigen,
- tumor microenvironment

FullText(HTML)

References(111)

References

[1]	Abraham RT, Weiss A (2004) Jurkat T cells and development of the T-cell receptor signalling paradigm. Nat Rev Immunol 4:301-308
[2]	Agrawal S, Kishore MC (2000) MHC class I gene expression and regulation. J Hematother Stem Cell Res 9:795-812
[3]	Akbar AN, Terry L, Timms A, Beverley PC, Janossy G (1988) Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells. J Immunol 140:2171-2178
[4]	Barfoed AM, Petersen TR, Kirkin AF, Thor Straten P, Claesson MH, Zeuthen J (2000) Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells in vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol 51:128-133
[5]	Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y et al (2013) Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma:intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 19:4792-4800
[6]	Bobisse S, Rondina M, Merlo A, Tisato V, Mandruzzato S, Amendola M, Naldini L, Willemsen RA, Debets R, Zanovello P et al (2009) Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res 69:9385-9394
[7]	Bobisse S, Foukas PG, Coukos G, Harari A (2016) Neoantigenbased cancer immunotherapy. Ann Transl Med 4:262
[8]	Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA (2014) Neo-antigens predicted by tumor genome metaanalysis correlate with increased patient survival. Genome Res 24:743-750
[9]	Byrne JA, Butler JL, Cooper MD (1988) Differential activation requirements for virgin and memory Tcells. J Immunol 141:3249-3257
[10]	Chen L, Flies DB (2013) Molecular mechanisms of T cell costimulation and co-inhibition. Nat Rev Immunol 13:227-242
[11]	Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A et al (2014) Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 20:2457-2465
[12]	Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-1310
[13]	Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, TrebskaMcGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS et al (2015) Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest 125:3981-3991
[14]	Corse E, Gottschalk RA, Allison JP (2011) Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol 186:5039-5045
[15]	Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes:at the core of cancer immunotherapy. Nat Rev Cancer 14:135-146
[16]	Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE (2010) Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 33:780-788
[17]	Cui G, Staron MM, Gray SM, Ho PC, Amezquita RA, Wu J, Kaech SM (2015) IL-7-induced glycerol transport and TAG synthesis promotes memory CD8+ T cell longevity. Cell 161:750-761
[18]	Debets R, Donnadieu E, Chouaib S, Coukos G (2016) TCRengineered T cells to treat tumors:Seeing but not touching? Semin Immunol 28:10-21
[19]	Dembic Z, Haas W, Weiss S, McCubrey J, Kiefer H, von Boehmer H, Steinmetz M (1986) Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 320:232-238
[20]	Deng R, Cassady K, Li X, Yao S, Zhang M, Racine J, Lin J, Chen L, Zeng D (2014) B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease. J Immunol 194:560-574
[21]	Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B (2009) T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113:6392-6402
[22]	Dillman RO, Barth NM, VanderMolen LA, Mahdavi K, McClure SE (2012) Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm 27:337-343
[23]	Draper LM, Kwong ML, Gros A, Stevanovic S, Tran E, Kerkar S, Raffeld M, Rosenberg SA, Hinrichs CS (2015) Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6. Clin Cancer Res 21:4431-4439
[24]	Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854
[25]	Fujio K, Misaki Y, Setoguchi K, Morita S, Kawahata K, Kato I, Nosaka T, Yamamoto K, Kitamura T (2000) Functional reconstitution of class Ⅱ MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. J Immunol 165:528-532
[26]	Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al(2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964
[27]	Germain RN, Stefanova I (1999) The dynamics of T cell receptor signaling:complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol 17:467-522
[28]	Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM et al (2016) Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nate Med 22:433-438
[29]	Harris TH, Banigan EJ, Christian DA, Konradt C, Tait Wojno ED, Norose K, Wilson EH, John B, Weninger W, Luster AD et al(2012) Generalized Levy walks and the role of chemokines in migration of effector CD8+ T cells. Nature 486:545-548
[30]	Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN et al(2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-567
[31]	Honda T, Egen JG, Lammermann T, Kastenmuller W, Torabi-Parizi P, Germain RN (2014) Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. Immunity 40:235-247
[32]	Howie B, Sherwood AM, Berkebile AD, Berka J, Emerson RO, Williamson DW, Kirsch I, Vignali M, Rieder MJ, Carlson CS et al.(2015). High-throughput pairing of T cell receptor alpha and beta sequences. Sci Transl Med 7,301ra131
[33]	Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR et al(2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535-546
[34]	Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S et al (2015) Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res 21:2268-2277
[35]	Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA (1994a) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91:3515-3519
[36]	Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994b) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458-6462
[37]	Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968
[38]	Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E (1998) The multi-epitope approach for immunotherapy for cancer:identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 59:1-14
[39]	Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704
[40]	Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN (2001) Immunotherapy through TCR gene transfer. Nat Immunol 2:957-961
[41]	Klebanoff CA, Rosenberg SA, Restifo NP (2016) Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med 22:26-36
[42]	Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM, Barsky LW, Chan R, Burotto F, Annett G et al(1998) T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med 4:775-780
[43]	Kunert A, van Brakel M, van Steenbergen-Langeveld S, da Silva M, Coulie PG, Lamers C, Sleijfer S, Debets R (2016) MAGE-C2-specific TCRs combined with epigenetic drug-enhanced antigenicity yield robust and tumor-selective T cell responses. J Immunol 197(6):2541-2552
[44]	Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V (2013) MHC class I antigen processing and presenting machinery:organization, function, and defects in tumor cells. J Natl Cancer Inst 105:1172-1187
[45]	Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ et al (2013) Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122:863-871
[46]	Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, Behjati S, Velds A, Hilkmann H, Atmioui DE et al (2015) High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 21:81-85
[47]	Loi S (2013) Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. OncoImmunology 2:e24720
[48]	Mahata B, Zhang X, Kolodziejczyk AA, Proserpio V, Haim-Vilmovsky L, Taylor AE, Hebenstreit D, Dingler FA, Moignard V, Gottgens B et al (2014) Single-cell RNA sequencing reveals T helper cells synthesizing steroids de novo to contribute to immune homeostasis. Cell Rep 7:1130-1142
[49]	Margulies DH (2001) TCR avidity:it's not how strong you make it, it's how you make it strong. Nat Immunol 2:669-670
[50]	Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK et al (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:400-404
[51]	Moon EK, Ranganathan R, Eruslanov E, Kim S, Newick K, O'Brien S, Lo A, Liu X, Zhao Y, Albelda SM (2016) Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res 22:436-447
[52]	Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007-1008
[53]	Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129
[54]	Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM et al(2013) Cancer regression and neurological toxicity following antiMAGE-A3 TCR gene therapy. J Immunother 36:133-151
[55]	Nishimura MI, Kawakami Y, Charmley P, O'Neil B, Shilyansky J, Yannelli JR, Rosenberg SA, Hood L (1994) T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines. J Immunother Emphasis Tumor Immunol 16:85-94
[56]	Obst R (2015) The timing of T cell priming and cycling. Front Immunol 6:563
[57]	Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T (2013) A rheostat for immune responses:the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14:1212-1218
[58]	Pageon SV, Tabarin T, Yamamoto Y, Ma Y, Bridgeman JS, Cohnen A, Benzing C, Gao Y, Crowther MD, Tungatt K et al (2016) Functional role of T-cell receptor nanoclusters in signal initiation and antigen discrimination. Proc Natl Acad Sci USA 113(37):E5454-E5463
[59]	Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, Rosenberg SA (2009) Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res 15:169-180
[60]	Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM et al(2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19:620-626
[61]	Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25:9543-9553
[62]	Pasetto A, Alena G, Robbins PF, Deniger DC, Prickett TD, MatusNicodemos R, Douek DC, Howie B, Robins H, Parkhurst MR et al(2016) Tumor-and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunology Research 4(9):734-743
[63]	Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA (2012a) Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal 5(230):ra46
[64]	Patsoukis N, Sari D, Boussiotis VA (2012b) PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle 11:4305-4309
[65]	Perez C, Jukica A, Listopad JJ, Anders K, Kuhl AA, Loddenkemper C, Blankenstein T, Charo J (2015) Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts. Int J Cancer 137:359-371
[66]	Phan GQ, Rosenberg SA (2013) Adoptive cell transfer for patients with metastatic melanoma:the potential and promise of cancer immunotherapy. Cancer Control 20:289-297
[67]	Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK et al(2012) Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 35:615-620
[68]	Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL et al (2014) MPDL3280A (antiPD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558-562
[69]	Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF et al (2016) Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. Cancer Immunol Res 4:669-678
[70]	Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G et al (2012) Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18:6758-6770
[71]	Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J et al(2015) NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 21:914-921
[72]	Redmond D, Poran A, Elemento O (2016) Single-cell TCRseq:paired recovery of entire T-cell alpha and beta chain transcripts in T-cell receptors from single-cell RNAseq. Genome Med 8(1):80
[73]	Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124-128
[74]	Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL et al(2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917-924
[75]	Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E et al (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747-752
[76]	Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM et al (2015) A pilot trial using lymphocytes genetically engineered with an NYESO-1-reactive T-cell receptor:long-term follow-up and correlates with response. Clin Cancer Res 21:1019-1027
[77]	Rolf J, Zarrouk M, Finlay DK, Foretz M, Viollet B, Cantrell DA (2013) AMPKalpha1:a glucose sensor that controls CD8 T-cell memory. Eur J Immunol 43:889-896
[78]	Rosenberg SA, Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:62-68
[79]	Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321
[80]	Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA et al (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676-1680
[81]	Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR et al(2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550-4557
[82]	Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712
[83]	Sanders ME, Makgoba MW, June CH, Young HA, Shaw S (1989) Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor-mediated activation. Eur J Immunol 19:803-808
[84]	Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538-18543
[85]	Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens:an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22-32
[86]	Semmling V, Lukacs-Kornek V, Thaiss CA, Quast T, Hochheiser K, Panzer U, Rossjohn J, Perlmutter P, Cao J, Godfrey DI et al(2010) Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol 11:313-320
[87]	Slifka MK, Whitton JL (2001) Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat Immunol 2:711-717
[88]	Smith-Garvin JE, Koretzky GA, Jordan MS (2009) T cell activation. Annu Rev Immunol 27:591-619
[89]	Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189-2199
[90]	Stronen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, Donia M, Boschen ML, Lund-Johansen F, Olweus J et al(2016) Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352:1337-1341
[91]	Tkach KE, Barik D, Voisinne G, Malandro N, Hathorn MM, Cotari JW, Vogel R, Merghoub T, Wolchok J, Krichevsky O et al (2014) T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks. Elife 3:e01944
[92]	Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS et al (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344:641-645
[93]	Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568-571
[94]	Uslu U, Schuler G, Dörrie J, Schaft N (2016) Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma. Exp Dermatol 25:872-879
[95]	Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L (2013) Trial Watch:Immunostimulatory cytokines. OncoImmunology 2:e24850
[96]	Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F et al (2000) Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 60:4499-4506
[97]	Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM et al(2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350:207-211
[98]	van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038-3043
[99]	Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51-64
[100]	van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJ, Behjati S, Hilkmann H, El Atmioui D et al (2013) Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31:e439-e442
[101]	Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H et al (2016) Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 536:91-95
[102]	von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Ødum N, Geisler C (2010) Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 11:344-349
[103]	Willinger T, Staron M, Ferguson SM, De Camilli P, Flavell RA (2015) Dynamin 2-dependent endocytosis sustains T-cell receptor signaling and drives metabolic reprogramming in T lymphocytes. Proc Nat Acad Sci 112:4423-4428
[104]	Wu AR, Neff NF, Kalisky T, Dalerba P, Treutlein B, Rothenberg ME, Mburu FM, Mantalas GL, Sim S, Clarke MF et al (2014) Quantitative assessment of single-cell RNA-sequencing methods. Nat Methods 11:41-46
[105]	Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H, Feldman SA, van der Bruggen P, Rosenberg SA et al (2016) Isolation and characterization of an HLA-DPB1^*04:01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. J Immunother 39:191-201
[106]	Yue C, Shen S, Deng J, Priceman SJ, Li W, Huang A, Yu H (2015) STAT3 in CD8+ T cells inhibits their tumor accumulation by downregulating CXCR3/CXCL10 axis. Cancer Immunol Res 3:864-870
[107]	Zhang N, Bevan MJ (2011) CD8(+) T cells:foot soldiers of the immune system. Immunity 35:161-168
[108]	Zhang Y, Stroobant V, Russo V, Boon T, van der Bruggen P (2002) A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes. Tissue Antigens 60:365-371
[109]	Zhang Y, Chaux P, Stroobant V, Eggermont AM, Corthals J, Maillere B, Thielemans K, Marchand M, Boon T, Van Der Bruggen P (2003) A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol 171:219-225
[110]	Zhang Y, Liu Y, Moxley KM, Golden-Mason L, Hughes MG, Liu T, Heemskerk MH, Rosen HR, Nishimura MI (2010) Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathog 6:e1001018
[111]	Zheng Y, Zha Y, Driessens G, Locke F, Gajewski TF (2012) Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med 209:2157-2163